Third Wave Completes FDA Submissions For Its Two HPV Products
May 15th 2008Drug InformationCervical Cancer
Third Wave Technologies Inc. (NASDAQ: TWTI) announced that the company has submitted the pre-market approval (PMA) applications for its two human papillomavirus, or HPV, testing products to the U.S. Food and Drug Administration. “The submission of Third Wave’s two HPV PMA applications marks the completion of a monumental undertaking by the entire Third Wave team,” said Kevin T. Conroy, president and chief executive of Third Wave.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
